Health and Healthcare
Drug Maker Staging a Comeback After Yesterday’s Debacle
Published:
Last Updated:
This was doubly bad news for Rigel, for which fostamatinib is its only drug with near-term economic potential. The company has other drugs in its pipeline, but only one is set to begin Phase II trials next year and others are even further in the future.
AstraZeneca has said it will continue with larger study on fostamatinib’s benefits, and that is probably what’s bringing Rigel a little relief today. AstraZeneca licensed the drug from Rigel for $100 million cash and a potential $345 million more if certain benchmarks are reached. Rigel could also receive up to $800 million in royalty payments once the drug hits the market.
Shares of Rigel are up 15.5% today after yesterday’s beating. Just before noon shares are trading at $6.36 in a 52-week range of $5.37 to $11.44.
Paul Ausick
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.